Form 4: Ionis Pharmaceuticals Director Michael R. Hayden Acquires Shares

Director Michael R. Hayden of Ionis Pharmaceuticals acquired 5,000 shares of common stock through two transactions on December 23, 2024.

Summary

• Michael R. Hayden, a director at Ionis Pharmaceuticals, purchased 2,500 shares of common stock at $36.1983 per share on December 23, 2024.
• He also purchased another 2,500 shares of common stock at $36.2332 per share on the same day.
• Following these transactions, Mr. Hayden directly owns 35,219 shares of Ionis Pharmaceuticals common stock.
• Additionally, 2,000 shares are indirectly owned through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as the director's purchase indicates confidence, but it's a routine transaction.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The increased holdings by a director can be seen as a positive signal to the market.

Industry Context

This is a routine disclosure of insider trading activity, which is common in publicly traded companies. It does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for all publicly listed companies, including those in the pharmaceutical sector.
• The volume of shares purchased is not unusual for a director's transaction.
• Similar transactions are regularly reported by directors and officers of comparable companies such as Alnylam Pharmaceuticals and Biogen.

Stakeholder Impact

• The stock purchase may have a slightly positive impact on shareholder confidence.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Ionis Pharmaceuticals, Michael R. Hayden, stock purchase, insider trading, director, common stock, share acquisition